Overview
The market for molecular in vitro diagnostic and screening tests for oncology totaled approximately $1.0bn in 2017, and is projected to expand at a compound annual growth rate (CAGR) of 13.1% during 2017-22, reaching an estimated $1.9bn. Geographic segments covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. Due to geographic trends in cancer incidence, there is considerable variation in market growth from one country/region to another. The greatest growth is projected for the RoW markets (at a 17.4% CAGR), followed by the US (14.1%), the 5EU countries (9.2%), and Japan (8.5%).
Key Questions Answered
Molecular Diagnostics Highlights
The market for molecular in vitro diagnostic and screening tests for oncology totaled approximately $1.0bn in 2017, and is projected to expand at a compound annual growth rate (CAGR) of 13.1% during 2017-22, reaching an estimated $1.9bn. Geographic segments covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. Due to geographic trends in cancer incidence, there is considerable variation in market growth from one country/region to another. The greatest growth is projected for the RoW markets (at a 17.4% CAGR), followed by the US (14.1%), the 5EU countries (9.2%), and Japan (8.5%).
Key Questions Answered
- What are the key drivers and limiters to this market?
- Which competitors are leading the market and introducing new technology?
- How are technological advancements impacting market growth?
- Which areas of the market are experiencing dynamic growth?
- How are mergers and acquisitions affecting the market shares of leading competitors?
Molecular Diagnostics Highlights
- The global market for molecular diagnostics for oncology totalled approximately $1.0bn in 2017, with the cervical cancer screening segment accounting for the largest share.
- The US remains the largest market, accounting for nearly 40% of sales in 2017, although regions outside the US represent good growth potential.
- Leading competitors in the market include Abbott, Agilent, Hologic, Qiagen, and Roche, among others.
Table of Contents
Executive Summary
Market Environment
Cancer Incidence and Prevalence by Type
Analytical Platforms for Molecular In Vitro Diagnostics for Oncology
Molecular In Vitro Diagnostic and Screening Tests for Oncology
